• Resp Care · Dec 2008

    Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.

    • Gail S Drescher, Bettye J Carnathan, Susan Imus, and Gene L Colice.
    • Pulmonary Services Department, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, USA. Gail.S.Drescher@medstar.net
    • Resp Care. 2008 Dec 1;53(12):1678-84.

    BackgroundTiotropium is used in maintenance treatment of chronic obstructive pulmonary disease (COPD), but there are no guidelines on when to start tiotropium following an exacerbation.ObjectiveTo determine whether the addition of tiotropium to a respiratory-therapist-directed bronchodilator protocol affects bronchodilator costs for patients hospitalized for COPD exacerbation.MethodsWe retrospectively analyzed data on the number and type of bronchodilator treatments administered to all patients admitted for COPD exacerbation during the 3-month period (January through March 2006) after tiotropium was added to our bronchodilator protocol, and compared that data to a historical control period (January through March 2004) before tiotropium was available in our hospital. We compared the costs of bronchodilator treatments, baseline patient characteristics, comorbidities, concomitant medications, length of stay, adverse events, and in-hospital deaths.ResultsBaseline characteristics, comorbidities, and concomitant medications were similar in the 2004 control group (n = 181) and the 2006 intervention group (n = 174). The mean +/- SD number of bronchodilator treatments per admission was significantly higher in the control period (13.6 +/- 15.6) than in the intervention period (10.6 +/- 9.4). That difference correlated to a reduction in combination therapy (short-acting inhaled beta(2) agonist plus ipratropium), which decreased from a per-admission average of 6.7 +/- 14.2 in the control period to 1.9 +/- 5.1 in the intervention period. Calculated bronchodilator costs were significantly lower in the intervention period than in the control period. Length of stay also significantly decreased, from 6.5 +/- 5.0 d to 5.5 +/- 4.0 d. There were no adverse events related to tiotropium. Pulmonary-related in-hospital deaths were not significantly different between the 2 periods.ConclusionsEarly addition of maintenance-treatment tiotropium to a respiratory-therapist-directed bronchodilator protocol for patients hospitalized for COPD exacerbation reduced costs and produced no safety concerns.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…